This study is in progress, not accepting new patients
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS)
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Ionis Pharmaceuticals, Inc.
- ID
- NCT04568434
- Phase
- Phase 3 Familial Chylomicronemia Syndrome Research Study
- Study Type
- Interventional
- Participants
- About 66 people participating
- Last Updated